As with our first immunotherapy, the second sensitiser, Phthalocyanine, has a long history of R&D and was approved in Russia in 2016. Our experience so far is limited to around 20 cases in combination with other treatments. In all cases we succeeded in initiating “Cancer Fever”.
Phthalocyanine has a more profound mode of immunological action when compared with Chlorin-Chlorophyll. However, Chlorin-Chlorophyll is extremely effective in reducing the burden of cancer and therefore should always be used first.
Benefits of Active Immunisation
Phthalocyanine is effective to:
- Follow up Chlorin-Chlorophyll to treat small undetected metastasis throughout the body
- Be used ahead of every chemotherapy cycle to prevent damage to the immune system
- Replace chemotherapy after an operation and/or radiation
Phthalocyanine as an additional treatment to standard chemotherapy is particularly interesting as it can take advantage of the chemotherapy to create an overall better result. It can be given alongside standard treatments or on its own. Chemotherapy normally depresses the body’s immune system and can cause severe side effects. The depressive effect of chemotherapy is counteracted because active immunotherapy with Phthalocyanine induces the immune system to attack the cancer. This immune response is very strong and gives “Cancer Fever”.
Over the past two years TippingPoint4Cancer has engineered:
- A pure isoform of the most immunising form of Phthalocyanine
- A delivery system, in the form of a lipoid, that attaches Phthalocyanine to the outer cell membrane of cancer cells where it attracts immune cells
- Pulsing LED Sources that make Phthalocyanine act in a similar way to a vaccine – See Figure 18
- Post treatment detoxification of Phthalocyanine
Supporting Evidence for this Unique Light Therapy
Preclinical research on Phthalocyanine in PDT dates to the 1960’s. Aluminium-Phthalocyanine-disulfonate was identified as the most effective molecule in animal studies. Extensive safety testing found it safe at high doses, up to 50 times the dose we use. In 2010 Phthalocyanine (Photosens) was registered in Russia based on an excellent application dossier. The Russian experience is vast and has been published. The principle sources were checked and re-published in French by Manneville and in English by Ben Hur. In 2012, the Russian Minister of Health approved guidelines for the use of Phthalocyanine.
One of the studies conducted in Russia was a Phase 2A Study in 42 humans with different types of untreatable cancers. Ninety two percent of patients responded to the treatment. Fifty percent obtained a complete remission and the remaining forty two percent had partial responses. The study used Phthalocyanine as an additional treatment to standard chemotherapy.
For further details please read the Phthalocyanine documentation